First Tracks Biotherapeutics (NASDAQ:TRAX) Receives Consensus Rating of “Buy” from Brokerages

First Tracks Biotherapeutics (NASDAQ:TRAX) has been given an average recommendation of “Buy” by the nine brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $38.25.

Several research firms have recently commented on TRAX. Leerink Partners began coverage on shares of First Tracks Biotherapeutics in a research report on Friday, April 24th. They set an “outperform” rating and a $46.00 target price for the company. Piper Sandler began coverage on shares of First Tracks Biotherapeutics in a research report on Monday, May 4th. They issued an “overweight” rating and a $54.00 price objective for the company. Wells Fargo & Company began coverage on shares of First Tracks Biotherapeutics in a research report on Monday, June 8th. They issued an “overweight” rating and a $30.00 price objective for the company. JPMorgan Chase & Co. began coverage on shares of First Tracks Biotherapeutics in a research report on Thursday, April 23rd. They issued an “overweight” rating and a $31.00 price objective for the company. Finally, Zacks Research raised shares of First Tracks Biotherapeutics to a “hold” rating in a research report on Monday, April 27th.

First Tracks Biotherapeutics Stock Performance

NASDAQ:TRAX opened at $17.14 on Wednesday. First Tracks Biotherapeutics has a one year low of $14.72 and a one year high of $26.80.